

GÃ©rard de Pouvoirville

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5239565/publications.pdf>

Version: 2024-02-01

55
papers

1,421
citations

430874

18
h-index

345221

36
g-index

72
all docs

72
docs citations

72
times ranked

2017
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance-Based Risk-Sharing Arrangementsâ€™ Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value in Health, 2013, 16, 703-719.	0.3	237
2	Valuing EQ-5D using Time Trade-Off in France. European Journal of Health Economics, 2013, 14, 57-66.	2.8	143
3	The efficiency frontier approach to economic evaluation of healthâ€™care interventions. Health Economics (United Kingdom), 2010, 19, 1117-1127.	1.7	97
4	Can economic evaluations be made more transferable?. European Journal of Health Economics, 2005, 6, 334-346.	2.8	80
5	A French Value Set for the EQ-5D-5L. Pharmacoeconomics, 2020, 38, 413-425.	3.3	74
6	Risk-sharing agreements for innovative drugs. European Journal of Health Economics, 2006, 7, 155-157.	2.8	70
7	Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Diabetes Care, 2021, 44, 1368-1376.	8.6	59
8	Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective caseâ€™control analysis. Clinical Therapeutics, 2008, 30, 2410-2422.	2.5	49
9	Assessment of the Cost of Fine-Needle Aspiration Cytology as a Diagnostic Tool in Patients With Thyroid Nodules. American Journal of Clinical Pathology, 2008, 129, 763-771.	0.7	48
10	Paying doctors for performance. European Journal of Health Economics, 2013, 14, 1-4.	2.8	48
11	Guidelines for completing the EURONHEED transferability information checklists. European Journal of Health Economics, 2009, 10, 157-165.	2.8	43
12	Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Nonâ€™Small Cell Lung Cancers. Journal of Thoracic Oncology, 2017, 12, 1496-1502.	1.1	34
13	Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. Journal of Medical Economics, 2019, 22, 289-296.	2.1	26
14	How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 641-650.	2.8	24
15	Cost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer. Value in Health, 2008, 11, 347-353.	0.3	24
16	Implications of learning effects for hospital costs of new health technologies: The case of intensity modulated radiation therapy. International Journal of Technology Assessment in Health Care, 2007, 23, 248-254.	0.5	22
17	Determinants of resource utilization in four palliative care units. Palliative Medicine, 2006, 20, 95-106.	3.1	21
18	Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. Health and Quality of Life Outcomes, 2018, 16, 28.	2.4	20

#	ARTICLE	IF	CITATIONS
19	Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. Journal of Medical Economics, 2012, 15, 225-232.	2.1	19
20	A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis. Medical Decision Making, 2009, 29, 125-139.	2.4	16
21	Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective. Archives of Cardiovascular Diseases, 2014, 107, 381-390.	1.6	16
22	AvaliaÃ§Ã£o dos Programas de SaÃºde: A EficiÃªncia em QuestÃ£o. Ciencia E Saude Coletiva, 1998, 3, 68-82.	0.5	16
23	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
24	Value of a QALY for France: A New Approach to Propose Acceptable Reference Values. Value in Health, 2020, 23, 985-993.	0.3	14
25	Cost of radiofrequency ablation in the treatment of hepatic malignancies. Gastroenterologie Clinique Et Biologique, 2007, 31, 828-835.	0.9	13
26	Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study. Archives of Cardiovascular Diseases, 2008, 101, 515-521.	1.6	13
27	Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. Journal of Market Access & Health Policy, 2017, 5, 1298190.	1.5	13
28	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. Current Medical Research and Opinion, 2019, 35, 785-792.	1.9	13
29	Costs associated with community acquired pneumonia in France. European Journal of Health Economics, 2018, 19, 533-544.	2.8	12
30	The cost of treating high blood pressure in general practice in France. European Journal of Health Economics, 2008, 9, 229-236.	2.8	10
31	The impact of research on hospital costs of care: an empirical study. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	10
32	The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France. European Journal of Health Economics, 2020, 21, 235-249.	2.8	10
33	Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France. Value in Health, 2022, 25, 605-613.	0.3	10
34	HAS to be NICE?. European Journal of Health Economics, 2013, 14, 363-366.	2.8	8
35	A French approach to cost-effectiveness analysis?. European Journal of Health Economics, 2010, 11, 521-523.	2.8	7
36	Public health research: between science and action?. Cadernos De Saude Publica, 1999, 15, 889-894.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 521-527.	1.9	6
38	Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals?. Health Policy, 2014, 116, 162-169.	3.0	6
39	26591 Characterization of flares in patients with generalized pustular psoriasisâ€”A population-based study from the French National Health Data System database (SNDS). Journal of the American Academy of Dermatology, 2021, 85, AB20.	1.2	6
40	Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. Journal of Scleroderma and Related Disorders, 2022, 7, 49-56.	1.7	5
41	Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. International Journal of Technology Assessment in Health Care, 2022, 38, e23.	0.5	5
42	Evaluation of Benefits Related to Reduced Length of Stays in Postanesthesia Care Units. International Journal of Technology Assessment in Health Care, 1998, 14, 172-179.	0.5	4
43	Treatment of Symptomatic Cholelithiasis in France: A Decision Analysis Comparing Cholecystectomy and Biliary Lithotripsy. International Journal of Technology Assessment in Health Care, 1992, 8, 166-184.	0.5	3
44	Hospital funding and competition. European Journal of Health Economics, 2004, 5, 3-5.	2.8	3
45	Quâ€™est-ce quâ€™une unitÃ© de soins Â«Â®performanteÂ®Â», du point de vue des malades relevant de soins palliatifs et de leurs prochesÂ?. Medecine Palliative, 2009, 8, 53-65.	0.0	3
46	Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study. Vaccine, 2021, 39, 5129-5137.	3.8	3
47	Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. Cerebrovascular Diseases, 2013, 35, 320-326.	1.7	2
48	Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France. Patient Related Outcome Measures, 2021, Volume 12, 237-246.	1.2	2
49	Time for a change in drug pricing : Going downstream. European Journal of Health Economics, 2002, 3, 140-141.	2.8	1
50	Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. American Journal of Clinical Dermatology, 2021, 22, 285-287.	6.7	1
51	Evaluation: the French chefs are still searching for "la nouvelle cuisine". Cadernos De Saude Publica, 1999, 15, 248-250.	1.0	1
52	A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France. Patient Related Outcome Measures, 2022, Volume 13, 21-30.	1.2	1
53	Health-related quality of lifeâ€™an economist's perspective. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 786-787.	2.8	0
54	Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20548-e20548.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Logique médicale, économique, industrielle et politique dans la définition du «prix» du médicament. Revue D'economie Financière, 2021, N° 143, 213-229.	0.1	0